Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Gilead Sciences Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $187.2B | |
|---|---|---|
| Revenue (ttm) | 30.5B | |
| Net income (ttm) | -3.2B | |
| EPS (ttm) | -$2.61 | |
| Shares out | 1.2B | |
| P/E (forward) | 15.4x | |
| Dividend | $3.28 (2.06%) | |
| Volume | 3,614,506 | |
| Beta | 0.33 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $27.31B | $27.28B | $27.12B | $28.75B | $29.44B | +1.9% |
| Gross profit | $20.70B | $21.62B | $27.12B | $22.50B | $23.21B | +2.9% |
| Operating income | $9.92B | $7.33B | $7.61B | $1.66B | $10.02B | +0.3% |
| Net income | $6.23B | $4.59B | $5.67B | $480.0M | $8.51B | +8.1% |
| EPS (diluted) | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 | +8.3% |
| EBITDA | $11.33B | $8.85B | $7.61B | $4.43B | $13.58B | +4.6% |
| R&D | $4.60B | $4.98B | $5.72B | $5.91B | $5.80B | +6.0% |
| SG&A | $5.25B | $5.67B | $6.09B | $6.09B | $5.77B | +2.4% |
Recent company headlines from major financial publishers.
FY2027 analyst consensus estimates support higher revenue and adjusted earnings. Growth then slows because HIV concentration limits the evidence for a longer expansion.
Improvement beyond FY2027 requires a larger non-HIV contribution and strong free cash flow. These are scenario conditions, while the cited evidence records FY2025 levels. Lower cell-therapy sales or weaker free cash flow would disconfirm this path.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 4.9% | $166 | $180 | $199 | $228 | $276 |
| 5.9% | $143 | $151 | $160 | $174 | $192 |
| 6.9% | $128 | $133 | $140 | $146 | $155 |
| 7.9% | $117 | $120 | $124 | $129 | $134 |
| 8.9% | $109 | $111 | $114 | $117 | $121 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
